The present invention provides for a transgenic non-human animal whose cells
contain a recombinant DNA sequence comprising a nerve tissue specific promoter
operatively linked to a DNA sequence which encodes amyloid-beta peptide alcohol
dehydrogenase (ABAD), and exhibits at least one phenotype from the group consisting
of: overexpression of ABAD, elevated levels of basal ATP; protection from metabolic
or ischemic stress.
